BRIEF published on 10/06/2025 at 15:00, 5 months 17 days ago Threshold crossing by the Caisse des dépôts et consignations in ABIONYX PHARMA Voting Rights CDC Threshold Crossing Bpifrance ABIONYX
BRIEF published on 10/06/2025 at 14:56, 5 months 17 days ago Threshold Crossing by Bpifrance at ABIONYX PHARMA Voting Rights Actions Threshold Crossing Bpifrance ABIONYX Pharma
BRIEF published on 10/06/2025 at 14:56, 5 months 17 days ago Franchissement de Seuil par Bpifrance chez ABIONYX PHARMA Droits De Vote Franchissement De Seuil Actions Bpifrance ABIONYX Pharma
PRESS RELEASE published on 10/06/2025 at 14:55, 5 months 17 days ago Franchissement de seuil Déclaration de franchissement de seuil pour ABIONYX PHARMA par la Caisse des dépôts et consignations via Bpifrance Participations Déclaration Franchissement De Seuil Bpifrance Caisse Des Dépôts ABIONYX Pharma
PRESS RELEASE published on 10/06/2025 at 14:51, 5 months 17 days ago Franchissement de seuil Déclaration de franchissement de seuil par Bpifrance concernant ABIONYX PHARMA sur Euronext Paris, le 29 septembre 2025 Euronext Paris Franchissement De Seuil Bpifrance ABIONYX Pharma 29 Septembre 2025
BRIEF published on 09/25/2025 at 20:21, 5 months 28 days ago ABIONYX Pharma : Résultats financiers du premier semestre 2025 Résultats Financiers Recherche Et Développement Trésorerie Plan France 2030 ABIONYX Pharma
BRIEF published on 09/25/2025 at 20:21, 5 months 28 days ago ABIONYX Pharma: Financial results for the first half of 2025 Financial Results Research And Development Treasury France 2030 Plan ABIONYX Pharma
PRESS RELEASE published on 09/25/2025 at 20:16, 5 months 28 days ago Informations privilégiées / Communiqué sur comptes, résultats ABIONYX Pharma annonce ses résultats financiers du 1er semestre 2025. Chiffre d'affaires de 2,1 M€, pertes réduites. Trésorerie à 3,4 M€. Lauréat du plan France 2030 Chiffre D'affaires Résultats Financiers Trésorerie ABIONYX Pharma 1er Semestre 2025
PRESS RELEASE published on 09/25/2025 at 20:16, 5 months 28 days ago Inside Information / News release on accounts, results ABIONYX Pharma announces its 2025 half-year financial results, including revenue of €2.1 million and ongoing initiatives in biotech innovation. Company receives government support for sepsis research Revenue Biotech Innovation ABIONYX Pharma 2025 Financial Results Sepsis Research
PRESS RELEASE published on 09/25/2025 at 18:58, 5 months 28 days ago Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Published on 03/24/2026 at 13:30, 45 minutes ago GGL Resources Corp. Announces Closing of Earn-In Agreement with Nelson Resources Limited on Its Gold Point High-Grade Gold-Silver Project, Nevada
Published on 03/24/2026 at 13:30, 45 minutes ago Innodata Announces Date of Annual Shareholder Meeting
Published on 03/24/2026 at 12:35, 1 hour 40 minutes ago Silver X Acquires the High-Grade Pampas Gold-Silver Project, Expanding its Precious Metal Asset Base in Peru
Published on 03/24/2026 at 12:33, 1 hour 42 minutes ago Mako Mining Completes Acquisition of Mt. Hamilton in Nevada
Published on 03/24/2026 at 12:30, 1 hour 45 minutes ago Orogen Reports Record 2025 Financial Performance and Positions for Continued Growth in 2026
Published on 03/24/2026 at 14:05, 9 minutes ago EPM Group selects OverIT's Field Service Management SaaS platform to modernise its field operations for over 3,000 users across LATAM
Published on 03/24/2026 at 14:05, 9 minutes ago The WATO Members Club: WATO calls the world's passionate of costumed parties
Published on 03/24/2026 at 14:00, 15 minutes ago Together We Build: Rentschler Biopharma celebrates Milford site progress and growth since U.S. expansion
Published on 03/24/2026 at 13:23, 51 minutes ago Turkiye Garanti Bankasi A.S.: Redemption of the debt instrument at abroad within the Medium Term Note (MTN) program
Published on 03/24/2026 at 13:05, 1 hour 9 minutes ago Fortegra Selects Duck Creek Reinsurance and Clarity to Support Strategic Growth
Published on 03/24/2026 at 10:58, 3 hours 16 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of February 28, 2026
Published on 03/24/2026 at 10:58, 3 hours 16 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 28 février 2026
Published on 03/24/2026 at 07:45, 6 hours 30 minutes ago François Jackow’s appointment as a Board member will be submitted to the Annual General Meeting on May 7, 2026
Published on 03/24/2026 at 07:45, 6 hours 30 minutes ago La nomination de François Jackow en tant que membre du Conseil d’administration sera soumise à l’Assemblée générale du 7 mai 2026
Published on 03/24/2026 at 07:30, 6 hours 45 minutes ago Gimv secures new EUR 400 million revolving credit facility to support accelerated growth ambitions
